Sophie Visonneau has served as Tocagen’s vice president of clinical operations since March 2018. She holds more than 25 years of experience across therapeutic areas, with a focus on oncology. Over the course of her career, which has spanned R&D functions in the pharmaceutical industry and academia, she has contributed to several investigational new drug applications (INDs), new drug applications (NDAs) and biologics license applications (BLA). She’s also helped design, conduct and analyze multiple global clinical trials that resulted in approved products and indication extensions.
Prior to joining Tocagen, Dr. Visonneau was the chief operating officer at Tioga Pharmaceuticals. Previous to this position, she was the senior director, head of global clinical operations at Shire Regenerative Medicine (previously Advanced BioHealing), where she built the company’s clinical operations group. Prior to this role, she was the vice president of clinical operations consulting for Polynoma, where she oversaw the planning and execution of a global registrational Phase 3 study of an oncology vaccine. Previous to this position she worked at Biogen Idec as the senior director of global clinical operations, responsible for the company’s oncology therapeutic area.
Prior to Biogen Idec, she held several positions of increasing responsibility at Amgen, including clinical leader of electronic common technical document (eCTD) modules 5 and 2 for the Vectibix global BLA submission in conjunction with a director role for global labeling in the Regulatory Affairs group; associate director and senior manager in the clinical research management function for the company’s oncology therapeutic area. Previous to this role she was the director of oncology therapeutic product development at Immunomedics. Immediately prior to this position she was a senior clinical scientist in the oncology clinical research North America group at SmithKline Beecham/GlaxoSmithKline where she led the development of three biologic and small molecule drug candidates from candidate selection through proof of concept, Phase 1 and Phase 2 clinical studies, and authored a patent on thrombopoietin mimetics.
Dr. Visonneau has authored more than 30 peer-reviewed publications and invited book chapters. She completed her post-doctoral fellowship, followed by a staff scientist position at The Wistar Institute. She received her Ph.D. in immunobiotechnology, master’s degree in immunology and bachelor’s degree in biochemistry from the Pierre and Marie Curie University of Sciences in Paris, France.